Coordinating and Data Management Center for the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer

Sponsor
M.D. Anderson Cancer Center (Other)
Overall Status
Unknown status
CT.gov ID
NCT03058926
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH), National Cancer Institute (NCI) (NIH), National Institutes of Health (NIH) (NIH)
25,000
1
35.4
706.5

Study Details

Study Description

Brief Summary

The data management systems, auditing, and monitoring effort are supported by the MD Anderson Cancer Center Clinical Research Support Center (CRSC). The The Coordination and Data Management Center (CDMC) will provide high quality, efficient and consistent leadership and services in all aspects of data quality and assurance; data harmonization and management; while providing assistance to the projects in disseminating and interpreting those data. The CDMC PI will provide statistical (study design, analysis plans, data analysis, and interpretation), data management, and data monitoring/auditing (data quality assurance and harmonization) expertise for the proposed projects. The Cancer Center will have access to identifiable data from studies; analysis of this data will not be conducted under this protocol. Any future analysis conducted on data or specimens as part of CPDPC protocols will be conducted under a separate IRB approved data or lab protocol.

The CDMC will leverage existing support, infrastructure, and resources from the Data Management and Coordinating Center for the Global Cancer Early Detection and the clinical expertise of the Division of Pathology/Lab Medicine at MDACC.

Condition or Disease Intervention/Treatment Phase
  • Other: Data Management and Monitoring

Study Design

Study Type:
Observational
Anticipated Enrollment :
25000 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Coordinating and Data Management Center for the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer
Actual Study Start Date :
Jan 19, 2017
Anticipated Primary Completion Date :
Jan 1, 2020
Anticipated Study Completion Date :
Jan 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Chronic Pancreatitis

Other: Data Management and Monitoring
Clinical Research Support Center's Data Management and Multicenter Study Support (MCSS) teams responsible for monitoring protocol and regulatory compliance for all consortium studies. MCSS responsible for maintaining and tracking IRB approval and regulatory documents from each site throughout the life of the study.

Diabetes

Other: Data Management and Monitoring
Clinical Research Support Center's Data Management and Multicenter Study Support (MCSS) teams responsible for monitoring protocol and regulatory compliance for all consortium studies. MCSS responsible for maintaining and tracking IRB approval and regulatory documents from each site throughout the life of the study.

Pancreatic Cancer

Other: Data Management and Monitoring
Clinical Research Support Center's Data Management and Multicenter Study Support (MCSS) teams responsible for monitoring protocol and regulatory compliance for all consortium studies. MCSS responsible for maintaining and tracking IRB approval and regulatory documents from each site throughout the life of the study.

Outcome Measures

Primary Outcome Measures

  1. Protocol and Regulatory Compliance for Consortium Studies for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) [3 years]

    Clinical Research Support Center's Data Management and Multicenter Study Support (MCSS) will monitor data quality and protocol compliance at all participating institutions.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Participants with chronic pancreatis, diabetes, and pancreatic cancer recruited through Consortium.
Exclusion Criteria:
  • N/A

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Texas MD Anderson Cancer Center Houston Texas United States 77030

Sponsors and Collaborators

  • M.D. Anderson Cancer Center
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • National Cancer Institute (NCI)
  • National Institutes of Health (NIH)

Investigators

  • Principal Investigator: Ying Yuan, PHD, M.D. Anderson Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT03058926
Other Study ID Numbers:
  • PA16-0439
  • 1U01DK108328-01
First Posted:
Feb 23, 2017
Last Update Posted:
Jan 14, 2019
Last Verified:
Jan 1, 2019
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by M.D. Anderson Cancer Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 14, 2019